Past Funding Opportunities
Priority Projects
Title |
Lead PI |
|---|---|
Companion Circulating Tumour Cells Analysis to NCIC-CTG Clinical Trial |
Jeremy Squire, Queen’s University |
Circulating Tumor Cell analysis and characterization using novel microfiltration technology and FISH: A correlative biology companion study to the NCIC CTG Phase II Clinical Trial IND.205 |
Alison Allan, London Health Sciences Centre Research Inc. |
Quantifying the Effect of Notch Inhibition on Tumour-Initiating Cells of Gamma-Secretase Inhibitor (RO4929097) in Advanced, Triple Negative Breast Cancer and Other Solid Tumours |
Michael Reedijk, University Health Network |
Multi-Institution Study of DCE CT Imaging Biomarkers of Tumours Microvasculature in Metastatic Renal Cell Carcinoma Patients Treated with Sunitinib |
Masoom Haider, University Health Network |
A Pilot Study of BOLD MRI and FLT-PET in Patients with Locally Advanced Breast Cancer Undergoing Neoadjuvant Chemotherapy |
Mark Levine, McMaster University |
Imaging with 111In-Pertuzumab to predict response to Trastuzumab in HER2 Positive Metastatic Breast Cancer |
Mark Levine, McMaster University |
Genomics Path Study Feasibility Project |
Lillian Siu, University Health Network |
A Phase II Study of Sunitinib or Temsirolimus in Patients with Advanced Rare Tumours |
Elizabeth Eisenhauer, Queen’s University |
Small Projects
| Title | Lead PI, Institution | Award Total | Award Period |
|---|---|---|---|
Data Acquisition module for Real-Time Quantitative Ultrasound of neoadjuvant Chemotherapy Response Assessment |
Gregory Czarnota, Sunnybrook Health Sciences Centre |
$51,705 |
October 2010 – March 2011 |
Integrated Molecular Profiling of Patient derived Tumour Xenograft Models for Preclinical Evaluation of Targeted Drugs and Biomarker Discoveries |
Lillian Siu, University Health Network |
$104,455 |
October 2010 – March 2011 |
Drug Level Analysis Technologies for Personalized Cancer Therapy and High Impact |
Richard Kim, Lawson Health Research Institute |
$102,097.50 |
October 2010 – March 2011 |
Companion Pharmacogenetic Study of BR.24 |
Geoffrey Liu, University Health Network |
$88,140 |
October 2010 – March 2011 |
Identification and Validation of Plasma Biomarkers that Predict Response to Cediranib in Non-Small Cell Lung Cancer Patients |
Christina Addison, Ottawa Hospital Research Institute |
$70,696 |
October 2011 – March 2012 |
Evaluation of Correlative Biomarkers in Cervical Cancer Patients Treated with Temsirolimus, an Inhibitor of Mammalian Target of Rapamycin (mTOR) |
Elizabeth Eisenhauer, Queen’s University |
$55,140 |
October 2011 – March 2012 |
Companion Pharmacogenetic Study in the Ovarian Cancer ICON7 Trial |
Helen Mackay, University Health Network |
$100,000 | October 2011 – March 2012 |
Molecular Determinants of Outcome with mTOR Inhibition in Endometrial Cancer |
Amit Oza, University Health Network |
$68,789.63 |
October 2011 – March 2012 |
HICT Endorsed Trials
Title |
Lead PI |
TRT Site |
Award Total |
Award Period |
|---|---|---|---|---|
Randomised Phase III Study of Neo-Adjuvant Docetaxel and Androgen Deprivation Prior to Radical Prostatectomy Versus Immediate Radical Prostatectomy in Patients with High Risk, Clinically Localized Prostate Cancer |
Joseph Chin |
Lawson Health Research Institute |
$30,360 |
October 2011 - September 2012 |
A Phase I study of various administration schedules of RO4929097 with multiparameter assessment (biomarkers, pharmacokinetics, pharmacodynamics) in patients with advanced solid tumours |
Sebastien Hotte |
McMaster University |
$20,305 |
October 2011 – September 2012 |
A Phase I Dose Finding Study of the Combination of High-Dose Statin Agent (Rosuvastatin) with Erlotinib in Patients with Advanced Solid Malignancies with a Focus on Squamous Cell Carcinomas and NSCLC (OTT-08-07) |
Glen Goss |
Ottawa Hospital Research Institute |
$68,848 |
April 2011 – September 2012 |
A Multicentre Study Assessing 12-Weekly Intravenous Bisphosphonate Therapy in Women with Low Risk Bone Metastases from Breast Cancer using Bone Resorption Markers (ER 10-04, TRIUMPH) |
Mark Clemons |
Ottawa Hospital Research Institute |
$59,124 |
April 2011 – September 2012 |
Randomized Phase III Study of Optimal Sequencing of Hormonal Therapy and Radiation in Patients with T1-T3 Prostate Cancer (OTT-01-01) |
Shawn Malone |
Ottawa Hospital Research Institute |
$12,800 |
April 2011 – September 2011 |
A phase I study of R04929097 in combination with gemcitabine in patients with advanced solid tumors |
Phillipe Bedard |
University Health Network | $7,866.66 |
October 2011 – September 2012 |
The Role of VEGF-A Signaling in Maintenance of the Glomerular Filtration Barrier and Blood Pressure |
Malcolm Moore |
University Health Network |
$7,866.66 |
October 2011 – September 2012 |
A Phase 2 Study of GW786034 (Pazopanib) with or without Bicalutamide in Hormone Refractory Prostate Cancer |
Amit Oza |
University Health Network |
$7,866.66 |
October 2011 – September 2012 |
A Phase 2 Study of AZD0530 in Recurrent or Metastatic Soft Tissue Sarcoma |
Margaret Von Mehren |
University Health Network |
$9,403.33 |
October 2011 – September 2012 |
A Phase 2 Study of AZD0530 in patients with advanced, recurrent non-small cell lung cancer who have previously received platinum-based combination chemotherapy |
Natasha Leighl |
University Health Network |
$9,403.33 |
October 2011 – September 2012 |
A Phase 2 Study of AZD0530 as first line treatment in patients with metastatic or locally advanced gastric carcinoma |
Helen MacKay |
University Health Network |
$9,403.33 |
October 2011 – September 2012 |
A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer |
Pamela Goodwin |
University Health Network |
$15,925 |
October 2011 – September 2012 |
A Phase II Single Arm Study Of AUY922 In patients with metastatic pancreatic adenocarcinoma who are resistant to first line chemotherapy |
Malcolm Moore |
University Health Network |
$15,925 |
October 2011 – September 2012 |